Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper

The introduction of new therapeutic agents in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), including the new kinase inhibitor idelalisib, has changed the therapeutic landscape of these diseases. However, the use of idelalisib is associated with a peculiar profile of side effects,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuneo, Antonio, Barosi, Giovanni, Danesi, Romano, Fagiuoli, Stefano, Ghia, Paolo, Marzano, Alfredo, Montillo, Marco, Poletti, Venerino, Viale, Pierluigi, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585802/
https://www.ncbi.nlm.nih.gov/pubmed/30187496
http://dx.doi.org/10.1002/hon.2540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585802/
https://www.ncbi.nlm.nih.gov/pubmed/30187496
http://dx.doi.org/10.1002/hon.2540

Ejemplares similares